Recursion Pharmaceuticals (RXRX) Treasury Shares (2021 - 2025)
Historic Treasury Shares for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $30.6 million.
- Recursion Pharmaceuticals' Treasury Shares rose 6934.6% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 6934.6%. This contributed to the annual value of $27.3 million for FY2024, which is 7935.27% up from last year.
- Recursion Pharmaceuticals' Treasury Shares amounted to $30.6 million in Q3 2025, which was up 6934.6% from $21.7 million recorded in Q2 2025.
- Recursion Pharmaceuticals' Treasury Shares' 5-year high stood at $30.6 million during Q3 2025, with a 5-year trough of $76762.0 in Q2 2021.
- Its 5-year average for Treasury Shares is $13.4 million, with a median of $15.4 million in 2023.
- As far as peak fluctuations go, Recursion Pharmaceuticals' Treasury Shares surged by 905572.29% in 2022, and later surged by 211.83% in 2024.
- Recursion Pharmaceuticals' Treasury Shares (Quarter) stood at $478136.0 in 2021, then soared by 1341.96% to $6.9 million in 2022, then surged by 120.81% to $15.2 million in 2023, then surged by 79.35% to $27.3 million in 2024, then grew by 12.23% to $30.6 million in 2025.
- Its Treasury Shares was $30.6 million in Q3 2025, compared to $21.7 million in Q2 2025 and $26.2 million in Q1 2025.